Health systems spent 77% more on semaglutide, the active ingredient of Ozempic and Wegovy, between April 2023 and March 2024, compared to the prior year, according to Vizient’s Pharmacy Market Outlook.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
